EGFR and non-small cell lung carcinoma: In conclusion, our retrospective analysis suggests that, under standard-dose gefitinib, patients with lower trough concentration may be clinically equivalent to patients with higher trough concentration for NSCLC patients with EGFR sensitive mutations.